Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. Rising Incidence of Chronic Diseases
4.1.1.2. Increasing chemotherapy medicines
4.1.2. Restraints:
4.1.2.1. Stringent regulations
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter’s Five Forces Analysis
5.2 Regulatory Analysis
5.3 Supply Chain Analysis
5.4 Pricing Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Diabetic Peripheral Neuropathy
6.2.1. Introduction
6.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
6.3. Chemotherapy-induced Peripheral Neuropathy
6.4. Idiopathic Peripheral Neuropathy
6.5. Others
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Pharmacological Therapies
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.2.3. Pain Relievers
7.2.4. Anti-seizure Medications
7.2.5. Antidepressants
7.3. Non-pharmacological Therapies
7.3.1. Transcutaneous Electrical Nerve Stimulation
7.3.2. Plasma Exchange and Intravenous Immune Globulin
7.3.3. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals
8.2.1. Introduction
8.2.2. Market Size Analysis, USD Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Clinics
8.4. Ambulatory Centers
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. The U.K.
9.3.6.3. France
9.3.6.4. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User.
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Averitas Pharma
11.1.1. Company Overview
11.1.2. Form Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Cipla Laboratories
11.3. Merck and Co
11.4. Bristol Meyer Squibb
11.5. Reddy’s Lab
11.6. Elli Lilly and Company
11.7. Teva Pharmaceutical Industries
11.8. GlaxoSmithKline
11.9. Novartis AG
11.10. Abbott Laboratories
LIST NOT EXHAUSTIVE
12. Global Peripheral Neuropathy Market – DataM
12.1. Appendix
12.2. About Us and Method of Fixation
12.3. Contact Us